Total Kidney Volume and eGFR in Polycystic Kidney Disease

In this podcast, Drs. Roumie and Hung summarize the main findings from their study on "Target Emulation Trial: GLP1RA, SGLT2i, DPP4i for Kidney Outcome Prevention" on behalf of their colleagues.

In this podcast, Dr. Yu summarizes the main findings from his study on the "Relationship between Total Kidney Volume and eGFR in Autosomal Dominant Polycystic Kidney Disease" on behalf of his colleagues.

In this podcast, Dr. Rebholz summarizes the main findings from her study on "Proteomic Markers of Dietary Patterns, CKD Progression, and Mortality in the CRIC Study" on behalf of her colleagues.

Dr. Saland summarizes the main findings from his study on "Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Dr. McCausland summarizes the main findings from his study on "Effect of finerenone on eGFR slope across different levels of baseline albuminuria and eGFR: Insights from FINEARTS-HF" on behalf of his coauthors.

Dr. Parikh, Dr. Malhotra, and Dr. Thiessen Philbrook summarize the main findings from their study on "Dynamic Risk Prediction of Graft Failure After Deceased Donor Kidney Transplant" on behalf of the authors.

Drs. Dagmara Borzych-Dużałka and Khandelval summarize the main findings from their study on "Early-Start vs. Late-Start Icodextrin for Children Receiving Chronic Peritoneal Dialysis: Findings from the International Pediatric Peritoneal Dialysis Network".

In this podcast, Dr. Sumida summarizes the main findings from his study on "Comparative Effectiveness of Lubiprostone and Stool Softeners on Risk of Kidney Outcomes in Patients with CKD" on behalf of his coauthors.

In this podcast, Dr. Neuen summarizes the main findings from his study on "SGLT2 inhibition and hospitalizations in patients with CKD: Data from CREDENCE and a meta-analysis of CKD progression trials" on behalf of his colleagues.

In this podcast, Dr. Ghaddar summarizes the main findings from her study on "Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative Glomerulonephritis" on behalf of her colleagues.